Cancer Prevention Clinical Trials Network (CP-CTNet)

Application information for the 2024 Funding Opportunities, including information about the pre-application webinar and frequently asked questions are available on the Application Information 2024 page.

Grantee Details

Program Guidelines for CP-CTNet

The Program Guidelines (PDF, 488.63 KB) are available as a PDF.

Important Links

Clinical Trial Management Information can be found at CP-CTNet Instructions, Forms and Templates.

The data and biospecimens from several early phase prevention studies are available for request from the Cancer Data Access System (CDAS).

The link to the DMACC website can be found here: Data Management, Auditing and Coordinating Center (DMACC).

Newsletters

The CP-CTNet Newsletter shares programmatic and research updates for the Cancer Prevention Clinical Trials Network (CP-CTNet). See the latest and all previous issues on the DMACC website.

I-SCORE Meetings

The Investigators-Site Coordinators Opportunity for Research Excellence (I-SCORE) meetings are held annually to stimulate information sharing and collaborations among DCP staff and Consortia members and to develop strategies to scientifically and operationally enhance DCP’s research program.

2024 ISCORE will be held March 14, 15, 2024 at NCI Shady Grove. For more information visit https://events.cancer.gov/dcp/iscore.

How Investigators Can Use CP-CTNet to Conduct Their Own Research

Accruing adequate numbers of study participants is a persistent challenge, especially for independent researchers. CP-CTNet, a cancer prevention research cooperative agreement-funded network, can provide a rich resource of individuals at risk for cancer who may be interested in participating in clinical trials.

• An investigator interested in conducting a clinical trial with an agent ready for clinical testing can join a Lead Academic Organization to become an Affiliated Organization
• An investigator who wishes to provide an agent for clinical study (but not to perform the clinical trial) can discuss with NCI/DCP if the agent is appropriate for study in CP-CTNet and then enter into a formal agreement with NCI/DCP to allow CP-CTNet to perform the trial
• An investigator with a potential agent that requires more efficacy assessment or toxicology studies before moving to a clinical trial can be directed to the NCI/DCP PREVENT Cancer Preclinical Drug Development Program (PREVENT)

NCI/DCP has developed guidelines and processes to assist investigators in accessing CP-CTNet.

The CP-CTNet funding supports the Lead Academic Organizations (LAO) and the organizations affiliated with the LAO Sites. These funds are directed to the management and oversight of clinical trials, trial conduct, participant care as well as primary and major secondary endpoint analyses. Additional outside funds, such as those from institutional, foundation, or other grant programs may be utilized.

For more information, contact Eva Szabo, M.D., CP-CTNet Director, at szaboe@mail.nih.gov.

Program Contact(s)

Eva Szabo, M.D.
Email address: eva.szabo@nih.gov